株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

早漏症:パイプライン製品の分析

Premature Ejaculation - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232828
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.21円で換算しております。
Back to Top
早漏症:パイプライン製品の分析 Premature Ejaculation - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 46 Pages
概要

早漏症は、最も一般的な男性の性機能障害です。射精は中枢神経系によってコントロールされ、性的刺激や摩擦によって、脊髄を通って脳に電気信号が伝達されると起こります。素因としては、勃起不全、心的ストレス、脳内の化学伝達物質の活動に影響を及ぼす特定の薬物の摂取などがあります。治療には表面麻酔薬クリームや、抗うつ剤などが使われます。

当レポートでは、早漏症治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

早漏症の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン製品
  • 企業で開発中の製品

早漏症:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

早漏症の治療薬開発に従事している企業

  • Allergan Plc
  • Ixchelsis Ltd
  • NeuroHealing Pharmaceuticals Inc
  • Plethora Solutions Holdings Plc
  • SK Chemicals Co Ltd

薬剤プロファイル

  • (lidocaine + prilocaine)
  • IX-01
  • modafinil
  • NCE-405
  • onabotulinumtoxin A

早漏症:休止中のプロジェクト

早漏症:開発が中止された製品

早漏症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9262IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Ejaculation - Pipeline Review, H1 2017, provides an overview of the Premature Ejaculation (Male Health) pipeline landscape.

Premature ejaculation (PE) is also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Ejaculation - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Premature Ejaculation (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Ejaculation (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Premature Ejaculation (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Premature Ejaculation (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Premature Ejaculation (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Premature Ejaculation (Male Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Premature Ejaculation (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Premature Ejaculation (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Premature Ejaculation - Overview
    • Premature Ejaculation - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Premature Ejaculation - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Premature Ejaculation - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Ixchelsis Ltd
    • NeuroHealing Pharmaceuticals Inc
    • Plethora Solutions Holdings Plc
    • SK Chemicals Co Ltd
  • Premature Ejaculation - Drug Profiles
    • (lidocaine hydrochloride + prilocaine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IX-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • modafinil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCE-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxinA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Premature Ejaculation - Dormant Projects
  • Premature Ejaculation - Discontinued Products
  • Premature Ejaculation - Product Development Milestones
    • Featured News & Press Releases
      • Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation
      • Nov 11, 2014: Plethora Solutions Provides Company Update
      • Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU
      • Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment
      • Mar 11, 2014: Plethora Solutions Provides Company update
      • Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation
      • Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation
      • Jul 01, 2013: AGM Statement & PSD502 Regulatory Update
      • Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update
      • Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502
      • Dec 19, 2011: Plethora Provides Update On PSD502
      • Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation
      • May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting
      • Nov 19, 2009: Sciele Pharma Presents Pivotal Study For PSD502, The First Potential Treatment For Premature Ejaculation At The Sexual Medicine Society Of North America (SMSNA)
      • Aug 21, 2009: NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Premature Ejaculation, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Premature Ejaculation - Pipeline by Allergan Plc, H1 2017
  • Premature Ejaculation - Pipeline by Ixchelsis Ltd, H1 2017
  • Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2017
  • Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H1 2017
  • Premature Ejaculation - Pipeline by SK Chemicals Co Ltd, H1 2017
  • Premature Ejaculation - Dormant Projects, H1 2017
  • Premature Ejaculation - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Premature Ejaculation, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top